New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
16:08 EDTPDIIPDI, Inc. subsidiary acquires miRInform test assets from Asuragen
PDI, Inc. announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform Thyroid and Pancreas cancer test assets from privately held Asuragen. This acquisition marks the execution of PDI's strategy to create a commercially driven molecular diagnostics business and a commitment to developing new solutions for the thyroid and pancreatic cancer testing markets. This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include $8M in upfront cash, future commercial milestone-based payments and royalties.
News For PDII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
08:37 EDTPDIIPDI, Inc. does not view Digirad letter as meaningful offer to acquire PDI
Subscribe for More Information
October 29, 2014
17:29 EDTPDIIDigirad delivers letter to PDI expressing willingness to acquire company
Digirad Corporation (DRAD) announced that it has sent a letter to PDI (PDII), a healthcare commercialization services company, expressing its willingness to acquire the company, through an appropriate acquisition entity by merger or otherwise, for a premium to PDI's current market price, to be determined after due diligence and discussions with the company. Digirad anticipates the consideration would be comprised of cash and stock of Digirad at a ratio to be determined at a later date.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use